Clinical Trials Logo

Filter by:
NCT ID: NCT04086511 Completed - Clinical trials for Phenylketonuria (PKU)

PANDA: PKU Amino Acid Evaluation

PANDA
Start date: September 10, 2019
Phase:
Study type: Observational

Phenylketonuria (PKU) is a rare inherited metabolic disorder, where subjects are born with a genetic deficiency in the phenylalanine hydroxylase enzyme (PAH), which leaves them unable to convert Phenylalanine (Phe) into Tyrosine (Tyr). PKU patients have specific dietary needs and must follow a restrictive diet in the aim of preventing toxic levels of the amino acid phenylalanine (Phe) accumulation.

NCT ID: NCT04085614 Completed - Clinical trials for Coronary Artery Disease

Dynamic Coronary Roadmap for Contrast Reduction

DCR4Contrast
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

The Dynamic Coronary Roadmap is a commercially available product developed by Philips Medical Systems, a Philips Healthcare company. Dynamic Coronary Roadmap is a software medical device intended to provide a real-time and dynamic angiographic roadmap of coronary arteries. The angiographic roadmap is automatically generated from previously acquired coronary angiograms during the same procedure. Dynamic Coronary Roadmap overlays the angiographic roadmap on live 2D fluoroscopic images, thereby assisting the physician in navigating devices, e.g. (guide) wires, catheters, through the coronary arteries. This is a multi-center, prospective, unblinded, stratified 1:1 randomized controlled trial to assess whether using Dynamic Coronary Roadmap reduces the total iodinated contrast volume related to Percutaneous Coronary Intervention (PCI) compared to the control group without Dynamic Coronary Roadmap.

NCT ID: NCT04084964 Completed - Heart Failure Clinical Trials

Feasibility Study of a Home Hospitalisation Strategy for Patients With Heart Failure

NWECHANCE
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

This feasibility study is part of a larger interregional European project (NWE-Chance) financially supported by the 'Interreg North West Europe' program to develop and validate promising integrated eHealth applications combined with nanotechnology for hospitalisation of heart failure patients at home. For more information on this research project and the partners see http://www.nweurope.eu/nwe-chance

NCT ID: NCT04083612 Completed - Psoriasis Vulgaris Clinical Trials

Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients

BIOLOPTIM-IXE
Start date: May 4, 2020
Phase: Phase 4
Study type: Interventional

Biologics, such as ixekizumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. Within this study the investigators aim to investigate the predictive value of early serum trough levels of ixekizumab and determine the therapeutic window of ixekizumab in psoriasis patients.

NCT ID: NCT04082728 Completed - Surgery Clinical Trials

Evaluation of the Added Value of Metamizole to Standard Post-operative Treatment After Ambulant Surgery

Start date: November 28, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to investigate if the addition of metamizole to the standard post-operative treatment, i.e. paracetamol and ibuprofen, is superior in reducing post-operative pain on day 1 after ambulatory surgery compared to the standard post-operative treatment. Therefore, a mono-center, prospective, double-blind, randomized controlled superiority trail will be designed in order to investigate superiority of metamizole compared to the standard post-operative treatment in patients undergoing arthroscopic shoulder surgery.

NCT ID: NCT04081974 Completed - Clinical trials for Perfusion; Complications

Prevalence and Predictors of Distal Limb Ischemia in Minimally Invasive Cardiac Surgery.

Start date: November 25, 2019
Phase:
Study type: Observational

Peripheral arterial cannulation is a necessity for installation of cardiopulmonary bypass in minimally invasive cardiac surgery (MICS). In the vast majority of cases, the femoral artery is the preferred arterial cannulation site. Distal limb hypoperfusion and ischemia can occur in the cannulated limb since antegrade perfusion is not routinely provided. Furthermore, the diameter of the cannula required to maintain adequate cardiopulmonary bypass (CPB) flow is often approaching that of the patient's femoral artery diameter, compromising distal blood flow. The possibility of distal limb ischemia is often raised as a criticism to peripheral cannulation for cardiopulmonary bypass and by extent to minimally invasive cardiac surgery. Ischemia of the lower limb is of high incidence in patients undergoing extracorporeal membrane oxygenation (ECMO) therapy, in which the same femoral cannulation technique is used. Therefore this complication has extensively been described in ECMO literature. However, no clinical trials have been performed in patients undergoing MICS, despite the same cannulation and perfusion route. ECMO patients often differ from MICS patients in morbidity as well as in duration of cannulation. Up to now, one could not observe any clinical sequelae of limb ischemia in MICS patients but a formal study of distal leg perfusion in MICS is recommended to screen its safety and to identify possible risk factors.

NCT ID: NCT04080661 Completed - Psoriasis Vulgaris Clinical Trials

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.

BIOLOPTIM-SEC
Start date: March 22, 2018
Phase: Phase 4
Study type: Interventional

Biologics such as secukinumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described according to a'one dose fits all' dosing regimen, leading to potential over-and undertreatment. In this study we aim to investigate the predictive value of early serum trough levels of secukinumab and determine the therapeutic window of secukinumab in psoriasis patients.

NCT ID: NCT04080648 Completed - Psoriasis Vulgaris Clinical Trials

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

BIOLOPTIM-GUS
Start date: June 27, 2018
Phase: Phase 4
Study type: Interventional

Biologic such as guselkumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. In this study we aim to investigate the predictive value of early serum trough levels of guselkumab and determine the therapeutic window of guselkumab in psoriasis patients.

NCT ID: NCT04078945 Completed - Shoulder Injuries Clinical Trials

Risk Factors of Shoulder Injuries in Youth Volleyball Players

Start date: September 1, 2019
Phase:
Study type: Observational

Shoulder injuries are usual in volleyball players. Nowadays, few prospective studies assessed risk factors of shoulder injuries in this sport. So, the objective of this study is to assess the risk factors of injuries in youth volleyball players. For that purpose, the following factors will be taken into consideration : shoulder internal/external rotators strength, shoulder range of motion, scapular dyskinesis, functional tests (medicine ball throw and upper quarter Y balance test), training load and psychosocial factors (POMS questionnaire).

NCT ID: NCT04078815 Completed - Heart Arrest Clinical Trials

End-of-life Practices in 2019 vs. 2014

Start date: September 3, 2019
Phase:
Study type: Observational

In 2014, the authors conducted a survey of key opinion leaders on ethical resuscitation practices in 31 European Countries. The authors administered a comprehensive questionnaire to 1-2 ʺexpertsʺ from each country; subjectivity-related bias could not be excluded; however, the questionnaire was actually administered twice over a 6-month period to all participants, in order to confirm results' reproducibility. The questionnaire spanned across the following 4 domains: A: ethical practices (41 questions); B: access to best available care (39 questions); C: death diagnosis and organ donation (22 questions); and D: emergency care organization (40 questions). Accordingly, a 142-point scoring system of the responses of the participants was developed. Country-specific scores varied widely [e.g. score range of 1-41 for the ethical practices (domain A), and of 9-32 for emergency care organization (domain D)]. The authors also found a significant association between domain A and domain D scores (r2 = 0.42, P < 0.001). The results of the 2014 survey highlighted variability across European countries in their approach to the ethics of resuscitation/end-of-life care. Results also indicated the presence of substantial need for improvements in all the aforementioned domains of practice and emergency care organization On the other hand, such evolution should be substantially augmented and accelerated by the above-described combination of new guidelines, RCT-based support of ACP, legislation / governmental policies, and educational activities. With this study the authors undertake a methodologically improved version of the 2014 survey, in order to test the following hypotheses: 1) compared to 2014, there may be significant improvements in overall domain A to D scores for 2019, reflecting improved quality of ethical practice in the field of resuscitation/end-of-life care; 2) such progress, may be more marked in countries with ʺlowʺ (i.e. below-average) domain A to D scores for 2014.